Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.88 |
| ▸ | MTOR | P42345 | 8/20 | 0.88 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.88 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.88 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.88 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.88 |
| ▸ | PRKDC | P78527 | 1/20 | 0.88 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.88 |
| ▸ | RICTOR | Q6R327 | 1/20 | 0.88 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.88 |
| ▸ | PIK3C3 | Q8NEB9 | 1/20 | 0.88 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.88 |
| ▸ | MAPKAP1 | Q9BPZ7 | 1/20 | 0.88 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.88 |
| ▸ | IRAK3 | Q9Y616 | 1/20 | 0.88 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Omipalisib SCHEMBL29352875 | 0.93 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL623194 | 0.93 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| Omipalisib SCHEMBL29358168 | 0.93 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL21189457 | 0.89 | PIK3C3 (0.70) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL741445 | 0.85 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL31299748 | 0.84 | PIK3CA (0.73) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL16454210 | 0.84 | PIK3CA (0.83) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL23121496 | 0.83 | PIK3CA (0.82) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL17060446 | 0.83 | PIK3CA (1.00) | PIK3CAMTORPIK3CDPIK3CBPIK3CG | |
| SCHEMBL25495105 | 0.83 | PIK3CA (0.84) | PIK3CAMTORPIK3CDPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2022-04-26 | — | — | US | disclosed |
| US-20200360386-A1 | Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions | UNITY BIOTECHNOLOGY, INC. | 2020-11-19 | — | — | US | disclosed |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-05-28 | — | — | US | disclosed |
| WO-2019032640-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/MTOR AND MEK/PI3K/MTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-02-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11311624-B2 | Inhibitors of MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR and MEK/PI3K/mTOR biological pathways and methods for improving lymphatic uptake, bioavailability, and solubility of therapeutic compounds | MTOR, JAK2, JAK1 | PIK3CA 14/4885MTOR 1/4885PIK3CD 32/4885 |
| US-20200360386-A1 | Inhibitors of HSP90, PI3-Kinase, Proteasome, HDAC, and P97 Pathways for Selective Removal of Senescent Cells in the Treatment of Age Related Conditions | HSP90AB1, HSP90AB2P, HSP90AA1 | PIK3CA 156/4885MTOR 16/4885PIK3CD 340/4885 |
| US-20200164081-A1 | INHIBITORS OF MEK/PI3K, JAK/MEK, JAK/PI3K/mTOR AND MEK/PI3K/mTOR BIOLOGICAL PATHWAYS AND METHODS FOR IMPROVING LYMPHATIC UPTAKE, BIOAVAILABILITY, AND SOLUBILITY OF THERAPEUTIC COMPOUNDS | MTOR, JAK2, JAK1 | PIK3CA 14/4885MTOR 1/4885PIK3CD 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.